Off-label indications for antidepressants in primary care: Descriptive study of prescriptions from an indication based electronic prescribing system

BMJ (Online)

Volumn 356, Issue , 2017, Pages

  Wong, Jenna ^a   Motulsky, Aude ^a,b   Abrahamowicz, Michal ^a   Eguale, Tewodros ^a   Buckeridge, David L ^a   Tamblyn, Robyn ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; MIRTAZAPINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; CANADA; DEPRESSION; DRUG INDICATION; DRUG MONITORING; ELECTRONIC PRESCRIBING; FEMALE; GENERAL PRACTITIONER; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; PAIN; PANIC; PRIMARY MEDICAL CARE; TREATMENT OUTCOME; TREATMENT PLANNING; URBAN AREA; AGED; CLINICAL PRACTICE; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; PREVALENCE; PRIMARY HEALTH CARE; PROCEDURES; QUEBEC; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ELECTRONIC PRESCRIBING; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; PHYSICIANS, PRIMARY CARE; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE; PRIMARY HEALTH CARE; QUEBEC;

EID: 85013999607     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j603     Document Type: Article

References (46)

1. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 2009;339:b3999. doi:10.1136/bmj.b3999.
2. Prescribing and Medicines Team, Health and Social Care Information Centre. Prescriptions dispensed in the community: England 2005-2015. 2016. https://digital.nhs.uk/catalogue/PUB20664/pres-disp-com-eng-2005-15-rep.pdf
3. Hemels MEH, Koren G, Einarson TR. Increased use of antidepressants in Canada: 1981-2000. Ann Pharmacother 2002;36:1375-9. doi:10.1345/aph.1A331.
4. National Center for Health Statistics. Health, United States, 2010 with special feature on death and dying. 2011. https://www.cdc.gov/nchs/data/hus/hus10.pdf
5. Stone KJ, Viera AJ, Parman CL. Off-label applications for SSRIs. Am Fam Physician 2003;68:498-504.
6. Li Y, Salmasian H, Harpaz R, Chase H, Friedman C. Determining the reasons for medication prescriptions in the EHR using knowledge and natural language processing. AMIA Annu Symp Proc 2011;2011:768-76.
7. Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med 2012;172:781-8. doi:10.1001/archinternmed.2012.340.
8. Wong J, Motulsky A, Eguale T, Buckeridge DL, Abrahamowicz M, Tamblyn R. Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006-2015. JAMA 2016;315:2230-2. doi:10.1001/jama.2016.3445.
9. Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics 2009;37:476-86, 396. doi:10.1111/j.1748-720X.2009.00408.x.
10. O'Malley PG: What does off-label prescribing really mean?Arch Intern Med 2012;172:759-60
11. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65:959-65. doi:10.4088/JCP.v65n0712.
12. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont) 2009;6:16-8.
13. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016;85:270-88. doi:10.1159/000447034.
14. Eom C-S, Lee H-K, Ye S, Park SM, Cho K-H. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res 2012;27:1186-95. doi:10.1002/jbmr.1554.
15. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014;109:811-9. doi:10.1038/ajg.2014.82.
16. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009;7:1314-21. doi:10.1016/j.cgh.2009.08.019.
17. Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012;87:982-90. doi:10.1016/j.mayocp.2012.04.017.
18. Eguale T, Buckeridge DL, Verma A, et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med 2016;176:55-63. doi:10.1001/jamainternmed.2015.6058.
19. Pomey M-P, Forest P-G, Palley HA, Martin E. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States. Milbank Q 2007;85:469-98. doi:10.1111/j.1468-0009.2007.00496.x.
20. Tamblyn R, Huang A, Kawasumi Y, et al. The development and evaluation of an integrated electronic prescribing and drug management system for primary care. J Am Med Inform Assoc 2006;13:148-59. doi:10.1197/jamia.M1887.
21. Eguale T, Winslade N, Hanley JA, Buckeridge DL, Tamblyn R. Enhancing pharmacosurveillance with systematic collection of treatment indication in electronic prescribing: a validation study in Canada. Drug Saf 2010;33:559-67. doi:10.2165/11534580-000000000-00000.
22. Vigilance Santé. www.vigilance.ca/en/
23. Thomson Micromedex. Drugdex system (internet database). Greenwood Village, Colo. https://micromedex.com/compendia
24. Center for Medicare Advocacy. CMA report: Medicare coverage for off-label drug use. 2010. www.medicareadvocacy.org/cma-report-medicare-coverage-for-off-label-drug-use/
25. Walton SM, Schumock GT, Lee K-V, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 2008;28:1443-52. doi:10.1592/phco.28.12.1443.
26. Xiao Y, Abrahamowicz M. Bootstrap-based methods for estimating standard errors in Cox's regression analyses of clustered event times. Stat Med 2010;29:915-23. doi:10.1002/sim.3807.
27. Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. J Clin Psychiatry 2006;67:972-82. doi:10.4088/JCP.v67n0615.
28. Rost K, Smith R, Matthews DB, Guise B. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994;3:333-7. doi:10.1001/archfami.3.4.333.
29. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-6. doi:10.1001/archinte.166.9.1021.
30. Chen DT, Wynia MK, Moloney RM, Alexander GCUS. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf 2009;18:1094-100. doi:10.1002/pds.1825.
31. Ghinea N, Lipworth W, Kerridge I. Off-label promotion of prescription medicine is it ever justifiable?Ther Innov Regul Sci 2015;49:359-63doi:10.1177/2168479015570337.
32. Sbarbaro JA. Can we influence prescribing patterns?Clin Infect Dis 2001;33(Suppl 3):S240-4. doi:10.1086/321856.
33. Stafford RS. Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med 2008;358:1427-9. doi:10.1056/NEJMp0802107.
34. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24:1577-601. doi:10.1177/0269881110379307.
35. Campanelli CM. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31. doi:10.1111/j.1532-5415.2012.03923.x.
36. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med 2009;169:1745-7. doi:10.1001/archinternmed.2009.314.
37. Godwin M, Seguin R. Critical appraisal skills of family physicians in Ontario, Canada. BMC Med Educ 2003;3:10. doi:10.1186/1472-6920-3-10.
38. McAlister FA, Laupacis A, Wells GA, Sackett DL. Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-7. doi:10.1001/jama.282.14.1371.
39. Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol 2010;70:320-34. doi:10.1111/j.1365-2125.2010.03681.x.
40. Dieleman JP, van Wyk JT, van Wijk MAM, et al. Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin 2005;21:1461-8. doi:10.1185/030079905X61866.
41. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-7. doi:10.1186/CVM-2-5-205.
42. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:403-39. doi:10.1177/0269881114525674.
43. Bartlett G, Tamblyn R, Kawasumi Y, Poissant L, Taylor L. Nonparticipation bias in health services research using data from an integrated electronic prescribing project: The role of informed consent. Acta Bioeth 2005;11:145-59doi:10.4067/S1726-569X2005000200005.
44. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014;311:368-77. doi:10.1001/jama.2013.282034.
45. Wang B, Kesselheim AS. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review. BMJ 2015;351:h4679. doi:10.1136/bmj.h4679.
46. Katzman MA, Bleau P, Blier P, et al. Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14(Suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1.